AbbVie, AbCellera expand collaboration into T-cell engagers

AbbVie (NYSE:ABBV) and AbCellera (NASDAQ:ABCL) have expanded their collaboration to include the discovery of T-cell engagers for the treatment of cancer.

Under the deal, AbCellera (NASDAQ:ABCL) will lead discovery efforts, with AbbVie (NYSE:ABBV) retaining the right to

Leave a Reply

Your email address will not be published. Required fields are marked *